疫苗佐剂尤其是生物佐剂是疫苗研发中的重要组成部分。一些细菌鞭毛蛋白可激活TLR5，既能刺激机体产生特异性的体液和细胞免疫，又能调节黏膜免疫反应，成为目前疫苗佐剂研究的热点之一，但是Hp鞭毛蛋白不具备这种能力。因此，本课题组择了能与TLR5结合的沙门菌鞭毛蛋白Flic的D0和D1区结合Hp鞭毛蛋白FlaA的D2，D3区，构建了一种新型嵌合鞭毛蛋白CF，作为佐剂应用于Hp疫苗CTB-UE获得新的融合疫苗CCU，并初步证实CF和CCU都具备刺激TLR5的能力。在此基础上，拟采用蒙古沙鼠Hp感染模型，验证CCU的免疫原性、免疫特异性及治疗Hp感染的效果，评价CF的佐剂效应；通过检测与TLR5相关的下游分子IκB-α、JNK、p38MAPK等表达情况及沙鼠体内细胞因子种类和水平的变化，并结合TLR5免疫缺陷型小鼠模型实验，揭示CF在Hp疫苗中的免疫作用机制，为Hp疫苗佐剂研究提供新的思路和实验依据。

Vaccine adjuvants, especially biological adjuvant is an important part for vaccine development. Some bacterial flagella can activate TLR5 and then stimulate the bodyto produce mucosal immune response besides specific humoral and cellular immunity, which has become a hotspot in current vaccine adjuvants development. Therefore, a new chimeric flagellin(CF) was constructed by our group through combinating the TLR-5-activating D0&D1 domains of S. typhimurium Flic with D2&D3 domians of Hp FlaA. We gained a new fusion vaccine CCU by inserting the CF to the N-end of Hp accine CTB-UE and preliminary confirmed that CF and CCU could activate TLR5. The adjuvantivity of CF in CCU will be evaluated in vivo by mongolian gerbil Hp infection models. Moreover, the mechanism of CCU against Hp infection will be investigated through assaying the levels and types of antibodies. It will be revealed the immune protection mechanism of CCU through detecting expression of the molecules associated with TLR5（including IκB-α, pJNK , p38MAPK ）、other specific cytokines and supporting by the study of mice genetically deficient in Toll-like receptor 5 (TLR5). This work will contribute to the selection of adjuvant for Hp multi-epitope vaccine in theory and experiment.